Text Size

Proteomics Analysis for Recognition of Acute Cellular Rejection After Lung Transplantation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2008 by Hannover Medical School.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hannover Medical School
ClinicalTrials.gov Identifier:
NCT00558597
First received: November 14, 2007
Last updated: July 19, 2011
Last verified: September 2008
History of Changes
  Purpose

In patients with acute rejection after lung transplantation the peptide profile in broncho-alveolar lavage (BAL) and urine should be compared in order to identify a paradigm that allows an non-invasive rejection therapy.


Condition
Rejection
Lung Transplantation

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Proteomics Analysis for Recognition of Acute Cellular Rejection After Lung Transplantation

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hannover Medical School:

Biospecimen Retention:   Samples Without DNA

BAL (broncho alveolar lavage) urine


Estimated Enrollment: 60
Study Start Date: March 2008
Estimated Study Completion Date: December 2011
Groups/Cohorts
1
30 patients with stable graft function
2
30 patients with acute rejection after lung transplantation

Detailed Description:

Goal of the study is the establishment of biomarkers for early diagnosis of acute rejection, followed by a late validation of the paradigm with prospectively collected samples, which will be examined blinded.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

patients after lung transplantation

Criteria

Inclusion Criteria:

  • Patients with stable graft function
  • Patients with acute rejection

Exclusion Criteria:

  • Acute infection
  • BOS
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00558597

Contacts
Contact: Jens Gottlieb, Dr. med. +49-511-5320 ext 3560 gottlieb.jens@mh-hannover.de
Contact: Isabelle Bodmann +49-511-5320 ext 2667 bodmann.isabelle@mh-hannover.de

Locations
Germany
Hannover Medical School Recruiting
Hannover, Germany, 30625
Contact: Jens Gottlieb, Dr. med.     +49-511-5320 ext 3560     gottlieb.jens@mh-hannover.de    
Sub-Investigator: Markus Berkefeld, Dr. med.            
Sponsors and Collaborators
Hannover Medical School
Investigators
Principal Investigator: Jens Gottlieb, Dr. med. Hannover Medical School
  More Information

No publications provided

Responsible Party: Hannover Medical School, Medical School
ClinicalTrials.gov Identifier: NCT00558597     History of Changes
Other Study ID Numbers: 154
Study First Received: November 14, 2007
Last Updated: July 19, 2011
Health Authority: Germany: Ethics Commission

Keywords provided by Hannover Medical School:
Proteomics
Lung Transplantation

ClinicalTrials.gov processed this record on May 16, 2013